The Continuous Glucose Monitoring (CGM) Technology market outlook remains highly attractive, driven by expanding diabetic prevalence, reimbursement expansions, and consumer‑driven wearables. Competitive intensity is escalating as legacy players (Dexcom, Abbott) defend market share while new entrants leverage miniaturized optics and AI‑driven analytics, creating a moderately fragmented but rapidly consolidating landscape. Long‑term outlook points to double‑digit CAGR through 2035, underpinned by chronic disease management policies and integration of CGM data into telehealth ecosystems. Innovation is vibrant: closed‑loop insulin delivery, multi‑analyte sensors, and non‑invasive optical platforms are moving from pilot to commercialization, raising the technology ceiling. Demand outpaces supply in the near term, especially for next‑generation sensors with longer wear time, prompting capacity expansions and strategic partnerships. Key risks include regulatory delays, cybersecurity vulnerabilities, and potential reimbursement pull‑backs in major markets. Decision‑makers should prioritize portfolio diversification, invest in data‑platform capabilities, and monitor policy shifts to mitigate these risks. Overall, the market’s growth trajectory justifies increased R&D spend and strategic alliances to capture emerging value streams.